Neuropathological Features of Gaucher Disease and Gaucher Disease with Parkinsonism

Int J Mol Sci. 2022 May 23;23(10):5842. doi: 10.3390/ijms23105842.

Abstract

Deficient acid β-glucocerebrosidase activity due to biallelic mutations in GBA1 results in Gaucher disease (GD). Patients with this lysosomal storage disorder exhibit a wide range of associated manifestations, spanning from virtually asymptomatic adults to infants with severe neurodegeneration. While type 1 GD (GD1) is considered non-neuronopathic, a small subset of patients develop parkinsonian features. Variants in GBA1 are also an important risk factor for several common Lewy body disorders (LBDs). Neuropathological examinations of patients with GD, including those who developed LBDs, are rare. GD primarily affects macrophages, and perivascular infiltration of Gaucher macrophages is the most common neuropathologic finding. However, the frequency of these clusters and the affected anatomical region varies. GD affects astrocytes, and, in neuronopathic GD, neurons in cerebral cortical layers 3 and 5, layer 4b of the calcarine cortex, and hippocampal regions CA2-4. In addition, several reports describe selective degeneration of the cerebellar dentate nucleus in chronic neuronopathic GD. GD1 is characterized by astrogliosis without prominent neuronal loss. In GD-LBD, widespread Lewy body pathology is seen, often involving hippocampal regions CA2-4. Additional neuropathological examinations in GD are sorely needed to clarify disease-specific patterns and elucidate causative mechanisms relevant to GD, and potentially to more common neurodegenerative diseases.

Keywords: Gaucher disease; Lewy Body disorder; Lewy body; Parkinson disease; glucocerebrosidase; lysosomal storage disorder; neuropathology.

Publication types

  • Review

MeSH terms

  • Gaucher Disease* / complications
  • Gaucher Disease* / genetics
  • Gaucher Disease* / pathology
  • Glucosylceramidase / genetics
  • Humans
  • Infant
  • Lewy Body Disease* / genetics
  • Neuropathology
  • Parkinsonian Disorders* / pathology

Substances

  • Glucosylceramidase